Immunonanotherapeutics Providing a Th1-Biased Response
First Claim
Patent Images
1. A composition for treatment of a condition comprising:
- synthetic nanocarriers comprising (1) an immunofeature surface, and (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocarriers; and
a pharmaceutically acceptable excipient;
wherein the immunofeature surface does not comprise antigen that is relevant to treatment of the condition in an amount sufficient to provoke an adaptive immune response to the antigen that is relevant to treatment of the condition.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable.
-
Citations
58 Claims
-
1. A composition for treatment of a condition comprising:
-
synthetic nanocarriers comprising (1) an immunofeature surface, and (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocarriers; and a pharmaceutically acceptable excipient; wherein the immunofeature surface does not comprise antigen that is relevant to treatment of the condition in an amount sufficient to provoke an adaptive immune response to the antigen that is relevant to treatment of the condition. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 22)
-
-
18-21. -21. (canceled)
-
23-41. -41. (canceled)
-
42. A method comprising:
-
identifying a subject suffering from a condition; providing a composition that comprises synthetic nanocarriers that comprise (1) an APC targeting feature, and (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocarriers; and
a pharmaceutically acceptable excipient; andadministering the composition to the subject; wherein the administration of the composition does not further comprise co-administration of an antigen that is relevant to treatment of the condition.
-
-
43-56. -56. (canceled)
-
57. A method comprising:
-
providing a composition comprising synthetic nanocarriers that comprise a Th1 biasing immunostimulatory agent and an APC targeting feature; administering the composition to a subject; and administering an antigen to the subject to which a Th1 biased response is clinically beneficial at a time different from administration of the composition to the subject; wherein administration of the antigen comprises passive administration or active administration.
-
-
58-68. -68. (canceled)
Specification